Bayer halts riociguat mid-stage study over safety concerns
An independent data monitoring committee observed that patients taking the drug in the trial were at a possible increased risk for death and other severe adverse events as
Arna Pharma and Slate Run Pharmaceuticals have completed a joint venture (JV) to form a speciality pharmaceutical company in the US focusing on branded products, 505(b)(2) medicines, and specialised generics.
The new macromolecule features various specialized components that create a triple-play action to avoid drug resistance. A specialized component of the macromolecule allows better hydrogen bonds with electrostatic